Lipocalin 2 mediates appetite suppression during pancreatic cancer cachexia.

Lipocalin 2 mediates appetite suppression during pancreatic cancer cachexia.
复制标题

脂质运载蛋白 2 在胰腺癌恶病质期间介导食欲抑制。

DOI:
10.1038/s41467-021-22361-3
复制
发表时间:
2021-04-06
影响因子:
16.6
通讯作者:
Marks DL
Marks DL
中科院分区:
综合性期刊1区
文献类型:
--
作者:
Olson B;Zhu X;Norgard MA;Levasseur PR;Butler JT;Buenafe A;Burfeind KG;Michaelis KA;Pelz KR;Mendez H;Edwards J;Krasnow SM;Grossberg AJ;Marks DL

文献摘要

参考文献

被引文献

相似文献

Lipocalin 2 (LCN2) was recently identified as an endogenous ligand of the type 4 melanocortin receptor (MC4R), a critical regulator of appetite. However, it remains unknown if this molecule influences appetite during cancer cachexia, a devastating clinical entity characterized by decreased nutrition and progressive wasting. We demonstrate that LCN2 is robustly upregulated in murine models of pancreatic cancer, its expression is associated with reduced food consumption, and Lcn2 deletion is protective from cachexia-anorexia. Consistent with LCN2’s proposed MC4R-dependent role in cancer-induced anorexia, pharmacologic MC4R antagonism mitigates cachexia-anorexia, while restoration of Lcn2 expression in the bone marrow is sufficient in restoring the anorexia feature of cachexia. Finally, we observe that LCN2 levels correlate with fat and lean mass wasting and is associated with increased mortality in patients with pancreatic cancer. Taken together, these findings implicate LCN2 as a pathologic mediator of appetite suppression during pancreatic cancer cachexia. Lipocalin 2 (LCN2) has been recently identified as an endogenous regulator of appetite. Here, using pancreatic cancer as a model of cachexia, the authors demonstrate that LCN2 is a critical mediator of cancer-associated anorexia and may be therapeutically targeted to improve patient outcomes.
DOI: 10.1371/journal.pone.0067693
发表时间: 2013
期刊: PloS one
影响因子: 3.7
作者:
Eller K;Schroll A;Banas M;Kirsch AH;Huber JM;Nairz M;Skvortsov S;Weiss G;Rosenkranz AR;Theurl I
通讯作者: Theurl I
DOI: 10.1038/mt.2013.36
发表时间: 2013-06-01
期刊: MOLECULAR THERAPY
影响因子: 12.4
作者:
Hofmann, Ted J.;Otsuru, Satoru;Horwitz, Edwin M.
通讯作者: Horwitz, Edwin M.
DOI: 10.1016/j.bbi.2018.05.021
发表时间: 2018-10
期刊: Brain, behavior, and immunity
影响因子: --
作者:
Burfeind KG;Zhu X;Levasseur PR;Michaelis KA;Norgard MA;Marks DL
通讯作者: Marks DL
DOI: 10.2337/db09-1735
发表时间: 2010-06
期刊: Diabetes
影响因子: 7.7
作者:
Guo H;Jin D;Zhang Y;Wright W;Bazuine M;Brockman DA;Bernlohr DA;Chen X
通讯作者: Chen X
DOI: 10.2217/fon-2017-0141
发表时间: 2017-08-01
期刊: FUTURE ONCOLOGY
影响因子: 3.3
作者:
Currow, David C.;Skipworth, Richard J. E.
通讯作者: Skipworth, Richard J. E.